We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TXA127

News List

Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19 americanpharmaceuticalreview
August 06, 2020
Constant Therapeutics announced its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York.
TXA127 from Constant Therapeutics Tested in COVID-19 Trials americanpharmaceuticalreview
July 20, 2020
Constant Therapeutics announced its peptide drug TXA127 will be tested in a series of Phase 2 clinical trials in hospitalized COVID-19 patients who are not in the Intensive Care Unit (ICU).
TXA127 enters multiple Phase II trials in COVID-19 patients europeanpharmaceuticalreview
July 14, 2020
A pharmaceutical formulation of the human angiotensin peptide, TXA127, will enter Phase II trials in hospitalised COVID-19 patients not in intensive care.
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 americanpharmaceuticalreview
November 29, 2018
Constant Pharmaceuticals plans to begin a development program for its compound, TXA127, for the treatment of the rare pediatric disease, epidermolysis bullosa in collaboration with.....